Transversal animal model platform
Manager: Dr. Laurent Mailly, PhD
The UMR_S1110/LabEx HepSYS comprises a unique state-of-the-art animal facility platform including a BSL3 zone and a specific pathogen-free area to ensure that research programs involving specifically dedicated small animal models can be performed with optimal animal care/well-being and high scientific quality. Within this platform, we develop cutting-edge mouse models. Our innovative approaches include the engraftment of patient tissues to model patient-specific disease and in vivo CRIPSR/Cas9 gene editing for biomarker and target validation, pre-clinical drug development and precision medicine. The models are developed and maintained by a highly qualified licensed staff. The facility recently acquired a Sharp Propsect T1 ulrasound imaging system with the support of PLAN CANCER 2014-2019, which allows to monitor the evolution of liver disease in small animals using a non-invasive approach. Infrastructure and approaches are available to the scientific community within collaborations or fee-for-service agreements.
For more information please contact email@example.com
Manager: Dr. Christine Thumann and Dr. Emilie Crouchet
Our BSL3 laboratory offers a safe and contained environment for the production and manipulation of viruses such as HCV, HBV and HIV. It contains six class II biological safety cabinets, a Biomek NXP automated workstation for high-throughput manipulation and a Mithras LB 940 Multimode Microplate Reader from Berthold (equipped for luminescence, BRET, FRET, fluorescence and colorimetry). We offer our services to external users interested in using our technology and benefit from our expertise.
Translational medicine bioinformatics platform
Manager: Dr. Frank Juehling, PhD
The translational medicine bioinformatics platform is modeling cell circuits in human disease biology. A key expertise is the integration of cell, animal and patient data contributing to unravel novel therapeutic concepts and targets. Our expertise in computational analyses comprises single-cell transcriptomics and proteomics as well as data analyses from epigenetic (ChIP-seq), mutational (DNA-seq), and transcriptomic (RNA-seq) next-generation sequencing. Furthermore, we study functional gene pathway enrichment analysis and contribute to drug screen assessment using genome-wide and signature approaches (such as NanoString® technology). Additionally, the bioinformatics platform aims to integrate artificial intelligence approaches into their program.
For more information please contact firstname.lastname@example.org
Patient-derived liver spheroid platform
Manager: Dr. François Duong, PhD
The UMR_S1110/LabEx HepSYS patient-derived liver spheroid platform develops state-of-the-art models for the study of liver disease biology, the identification of novel therapeutic targets for prevention and treatment of HCC, and precision medicine. Our well-established 3D patient-derived spheroid culture, unlike organoids, harbors the full liver microenvironment and reproduces the physiopathology in patients. Therefore, this patient-derived model system offers the best model to perform proof-of-concept study and therapeutic efficacy validation of new anti-cancer drugs. This platform enables cutting-edge translational research for personalized medicine, for the upcoming concept of ‘clinical trial in a dish’ that revolutionizes drug development, moving promising drugs to clinical and public health practice for population health benefit.
For more information please contact email@example.com
Translational medicine platform
Clinical Investigators: Prof. François Habersetzer, MD, PhD & Dr. Simona Tripon, MD, PhD
UMR_S1110/LabEx HepSYS clinicians participate or lead randomized trials for the clinical development of antivirals or novel therapeutic strategies for NASH, liver cirrhosis and cancer.
Surgical Investigators: Prof. Patrick Pessaux, MD, PhD & Dr. Emanuele Felli, MD
UMR_S1110/LabEx HepSYS clinical research is developing innovative approaches to deliver personalized patient care by combining complementary technologies such as image-guided precision medicine incorporating artificial intelligence and precision genomics.
Our clinicians are responsible for Strasbourg University teaching in liver and gastrointestinal disease (medicine and surgery) at the Faculty of Medicine and the IHU (Institute of Image-Guided Surgery).
Master and PhD training in patient-related research including clinical trial design, data analyses and the study of patient samples is provided in collaboration with the other UMR_S1110/LabEx HepSYS principal investigators.